Drug Trial Radar · NCT01458639
Compare Technegas Ventilation-Perfusion SPECT and Xenon Ventilation-Perfusion Planar Imaging for Pulmonary Embolism
Last checked: Nov 19, 2026Latest source record: Nov 10, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
18
Actual
Start
Aug 2012
Primary completion
Jun 2015
Study completion Jun 2015
Sponsor
- Lead sponsor
- Cyclomedica Australia PTY LimitedIndustry
- Sponsor type
- Industry
- First posted
- Oct 25, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- Single (outcomes assessor)
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 3 within-subject trial of Technegas V/Q SPECT and Tc-99m macro-aggregated albumin (MAA) imaging compared to Xenon-133 V/Q planar and Tc-99m macroaggregate of albumin (MAA) imaging for the diagnosis of Pulmonary Embolism (PE).
Conditions
- Pulmonary Embolism
Interventions
Technegas V SPECT imagingDrug
Technegas V SPECT imaging and Technetium 99m MAA Perfusion imaging for the diagnosis pf pulmonary embolism.
Xenon-133 Ventilation Planar imagingDrug
Xenon-133 Ventilation Planar imaging and Technetium 99m MAA Perfusion imaging for the diagnosis pf pulmonary embolism.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sensitivity of Technegas V/Q SPECT for the Diagnosis of PETime frame: Prospective, 30 days follow-up
- Specificity of Technegas V/Q SPECT for the Diagnosis of PE.Time frame: Prospective, 30 days follow-up
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Barnes-Jewish Hospital, Washington University
St Louis, Missouri
Columbia University Medical Center
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.